I think they wouldn’t put the knife into us at these prices mate.at a 20% disc to raise enough to keep the lights on for 1 more year given the delays to RP11 revenues =~$36m required @ 4.9c = 734,693,877 new sharesthis will dilute us to oblivion, and assumes the multi-site global patient clinical trials won’t add more to the current quarterly burn rate
(20min delay)